Nifuraldezone is an antibacterial compound. It completely mimics the radiosensitizing effect of molecular oxygen in hypoxic mammalian cells in vitro at concentrations in tissue culture medium which showed no measurable acute toxicity.

Alipamide is an antihypertensive and diuretic agent. It is a hydrazide derivative of m-sulfamoylbenzoic acid with diuretic activity. Alipamide primarily causes a saluretic effect and is able to inhibit carbonic anhydrase at higher doses which may also contribute to this agent's diuretic effect.

Amquinate is a quinolone coccidiostat. It is a powerful inhibitior of succinate and malate plus pyruvate supported respiration in E. tenella mitochondria. Amquinate is an antimalarial drug.

BIPHENYL DIMETHYL DICARBOXYLATE (BDD) under the brand name Nissel is used in the South Corea for the treatment of chronic hepatitis followed by an increase in serum alanine aminotransferase levels continuously. This compound also participated in clinical trials phase III in the patients with chronic liver disease. In addition, the drug was studied in phase III clinical trials after laparoscopic cholecystectomy. The use of BDD in patients with cholecystitis was expected to inhibit elevated liver enzyme levels and to maintain liver function.

Dinsed is a coccidiostat used in poultry to stop the growth of coccidian parasites.

Thiphencillin is a penicillin analog patented by Abbott Laboratories as an antibacterial agent. Thiphencillin shows potent antibacterial activity against various species and genera of pathogenic bacteria.

Nafenopin is a hypolipidemic drug. It is also a peroxisome proliferator. In rats and mice, nafenopin is a nongenotoxic hepatocarcinogen, which induces hepatic DNA synthesis and enzyme induction both in vivo and in hepatocyte cultures in vitro. Hepatic Ca2+ mobilization induced by nafenopin may play an important role in the mechanism by which nafenopin exerts its physiological as well as its tumour promotive activity upon chronic treatment with carcinogenic doses.

Tibric Acid is a sulfamoylbenzoic acid derivative patented by American multinational pharmaceutical corporation Pfizer Inc. as a hypolipidemic agent. In preclinical models, Tibric acid, given orally, was more effective than clofibrate in preventing the hyperlipemic and hypercholesteremic effects of various diets in rats. At high concentrations in vitro, Tibric acid moderately inhibited ADP- or thrombin-induced aggregation of rabbit blood platelets. In patients with severe type IV hyperlipoproteinemia and chylomicronemia, Tibric Acid lowered serum triglyceride and cholesterol values but administration of Tibric Acid to a normal subject did not affect serum lipid levels.